Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23549784 | 1.00 | LMNA (0.31) | LMNAMAPTPOLB | |
| SCHEMBL15320374 | 0.83 | POLB (0.32) | POLB | |
| SCHEMBL104499 | 0.81 | LMNA (0.42) | LMNAMAPTPOLB | |
| SCHEMBL19331934 | 0.81 | LMNA (0.32) | LMNAMAPTPOLB | |
| SCHEMBL19716095 | 0.80 | LMNA (0.31) | LMNAMAPTPOLB | |
| SCHEMBL17868701 | 0.78 | — | — | |
| SCHEMBL2487318 | 0.75 | LMNA (0.34) | LMNAMAPTPOLB | |
| SCHEMBL21528223 | 0.75 | — | — | |
| SCHEMBL20163725 | 0.74 | ABCB1 (0.33) | POLB | |
| SCHEMBL18979169 | 0.73 | LMNA (0.34) | LMNAPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12202843-B2 | Muscarinic receptor agonists | NXERA PHARMA UK LIMITED (GB) | 2025-01-21 | — | — | US | disclosed |
| US-20240043436-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION | PMV PHARMACEUTICALS, INC. | 2024-02-08 | — | — | US | disclosed |
| US-11807644-B2 | Methods and compounds for restoring mutant p53 function | PMV PHARMACEUTICALS, INC. (US) | 2023-11-07 | — | — | US | disclosed |
| EP-4149459-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT P53 FUNCTION | PMV Pharmaceuticals, Inc. (US) | 2023-03-22 | — | — | EP | disclosed |
| US-20230002403-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION | PMV PHARMACEUTICALS, INC. | 2023-01-05 | — | — | US | disclosed |
| US-11440884-B2 | Compounds, salts thereof and methods for treatment of diseases | ACADIA PHARMACEUTICALS INC. (US) | 2022-09-13 | — | — | US | disclosed |
| US-20220048928-A1 | MUSCARINIC RECEPTOR AGONISTS | NXERA PHARMA UK LIMITED (GB) | 2022-02-17 | — | — | US | disclosed |
| WO-2021231474-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION | PMV PHARMACEUTICALS, INC. (US) | 2021-11-18 | — | — | WO | disclosed |
| CN-107530329-B | Pyrazolo [1, 5-a ] [1, 3, 5] triazine and pyrazolo [1, 5-a ] pyrimidine derivatives as CDK inhibitors | 奥瑞基尼探索技术有限公司 | 2021-10-08 | — | — | CN | disclosed |
| US-11034704-B2 | Muscarinic receptor agonists | NXERA PHARMA UK LIMITED (GB) | 2021-06-15 | — | — | US | disclosed |
| US-20130072427-A1 | GPR 119 MODULATORS | PFIZER INC. | 2013-03-21 | — | — | US | disclosed |
| WO-2013011402-A1 | GPR 119 MODULATORS | PFIZER INC. (US) | 2013-01-24 | — | — | WO | disclosed |
| US-20120295845-A1 | IMIDAZO-PYRAZOLES AS GPR119 INHIBITORS | PFIZER INC | 2012-11-22 | — | — | US | disclosed |
| EP-2504342-A1 | IMIDAZO-PYRAZOLES AS GPR119 INHIBITORS | Pfizer Inc. (US) | 2012-10-03 | — | — | EP | disclosed |
| WO-2012069948-A1 | 4- (5-CYANO-PYRAZOL-1-YL) -PIPERIDINE DERIVATIVES AS GPR 119 MODULATORS | PFIZER INC. (US) | 2012-05-31 | — | — | WO | disclosed |
| WO-2012069917-A1 | BICYCLIC GPR119 MODULATORS | LUPIN LIMITED (IN) | 2012-05-31 | — | — | WO | disclosed |
| US-20120052130-A1 | GPR 119 MODULATORS | PFIZER INC. | 2012-03-01 | — | — | US | disclosed |
| WO-2011061679-A1 | IMIDAZO-PYRAZOLES AS GPR119 INHIBITORS | PFIZER INC. (US) | 2011-05-26 | — | — | WO | disclosed |
| US-20100285145-A1 | GPR 119 MODULATORS | PFIZER INC | 2010-11-11 | — | — | US | disclosed |
| WO-2010069979-A1 | PYRAN DERIVATIVES AS CCR3 MODULATORS | NYCOMED GMBH (DE) | 2010-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120052130-A1 | GPR 119 MODULATORS | GPR119, GPR39, GPR65 | LMNA 3794/4885MAPT 4026/4885POLB 4573/4885 |
| US-20220048928-A1 | MUSCARINIC RECEPTOR AGONISTS | CHRM1, CHRM2, CHRM3 | LMNA 2166/4885MAPT 2825/4885POLB 3547/4885 |
| US-12202843-B2 | Muscarinic receptor agonists | CHRM1, CHRM2, CHRM3 | LMNA 2166/4885MAPT 2825/4885POLB 3547/4885 |
| US-20230002403-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION | TP53, TP53BP1, HRAS | LMNA 2728/4885MAPT 4180/4885POLB 76/4885 |
| US-20130072427-A1 | GPR 119 MODULATORS | GPR119, GPR65, GPR39 | LMNA 3958/4885MAPT 3590/4885POLB 4496/4885 |
| US-11440884-B2 | Compounds, salts thereof and methods for treatment of diseases | SLC10A1, VHL, CYP11B2 | LMNA 1469/4885MAPT 1266/4885POLB 1110/4885 |
| US-20100285145-A1 | GPR 119 MODULATORS | GPR119, GPR65, GPR39 | LMNA 3958/4885MAPT 3590/4885POLB 4496/4885 |
| US-11807644-B2 | Methods and compounds for restoring mutant p53 function | TP53, TP53BP1, HRAS | LMNA 2728/4885MAPT 4180/4885POLB 76/4885 |
| US-20240043436-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION | TP53, TP53BP1, HRAS | LMNA 2728/4885MAPT 4180/4885POLB 76/4885 |
| US-11034704-B2 | Muscarinic receptor agonists | CHRM1, CHRM2, CHRM3 | LMNA 2166/4885MAPT 2825/4885POLB 3547/4885 |
| US-20120295845-A1 | IMIDAZO-PYRAZOLES AS GPR119 INHIBITORS | GPR3, GPR119, GPR84 | LMNA 3214/4885MAPT 4845/4885POLB 4403/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.